Stock Events

Haemonetics 

€82
2
-€0.5-0.61% Friday 07:28

Statistics

Day High
82
Day Low
82
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
4.52B
P/E Ratio
38.46
Dividend Yield
-
Dividend
-

Earnings

9MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
0.68
0.8
0.93
1.05
Expected EPS
0.89
Actual EPS
0.9

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HAZ.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Baxter International
BAX
Mkt Cap18.01B
Baxter International Inc. offers a range of products in blood and plasma collection, a direct competition to Haemonetics' blood processing systems.
Becton Dickinson
BDX
Mkt Cap66.69B
Becton, Dickinson and Company provides a variety of medical devices and supplies, including blood collection and management solutions, competing in similar markets as Haemonetics.
Thermo Fisher Scientific
TMO
Mkt Cap203.97B
Thermo Fisher Scientific Inc. supplies a wide range of laboratory equipment and consumables, including those for blood and plasma collection and analysis, overlapping with Haemonetics' offerings.
Danaher
DHR
Mkt Cap180.39B
Danaher Corporation's life sciences and diagnostics segments offer products and solutions that compete with Haemonetics in the blood management and diagnostics market.
Mettler-Toledo International
MTD
Mkt Cap28.71B
Mettler-Toledo International Inc. competes in the precision instruments sector, including laboratory equipment and diagnostics that can be used in blood analysis, indirectly competing with Haemonetics.
Resmed
RMD
Mkt Cap29.84B
ResMed Inc. is more focused on sleep and respiratory care, but its expansion into healthcare solutions and monitoring technologies presents a competitive edge in the broader healthcare market against Haemonetics.
Boston Scientific
BSX
Mkt Cap114.03B
Boston Scientific Corporation, while primarily focused on medical devices for interventional medical specialties, competes in the healthcare market where Haemonetics also operates, especially in patient care and treatment technologies.
Stryker
SYK
Mkt Cap129.88B
Stryker Corporation, known for medical devices and equipment, competes in the healthcare market, offering products that can be used in surgeries and medical treatments where blood management is crucial.
Abbott Laboratories
ABT
Mkt Cap177.49B
Abbott Laboratories offers a broad range of healthcare products, including diagnostics and medical devices that compete with Haemonetics in the healthcare and diagnostics market.
Johnson & Johnson
JNJ
Mkt Cap372.29B

Analyst Ratings

114.67Average Price Target
The highest estimate is €125.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

About

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Show more...
CEO
Mr. Christopher A. Simon
Employees
3657
Country
US
ISIN
US4050241003
WKN
000881782

Listings